Immunic, Inc. is a clinical-stage biopharmaceutical company that develops selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases. Their lead program IMU-838 is in Phase 2 clinical for treating multiple sclerosis, inflammatory bowel disease, and to combat COVID-19. The company also has other programs to treat intestinal diseases like IMU-935 and IMU-856.